Bielefeldt Andreas Ø, Danborg Pia B, Gøtzsche Peter C
Nordic Cochrane Centre, Rigshospitalet, 2100 Copenhagen Ø, Denmark.
Nordic Cochrane Centre, Rigshospitalet, 2100 Copenhagen Ø, Denmark Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark.
J R Soc Med. 2016 Oct;109(10):381-392. doi: 10.1177/0141076816666805.
To quantify the risk of suicidality and violence when selective serotonin and serotonin-norepinephrine reuptake inhibitors are given to adult healthy volunteers with no signs of a mental disorder.
Systematic review and meta-analysis.
Harms related to suicidality, hostility, activation events, psychotic events and mood disturbances.
Published trials identified by searching PubMed and Embase and clinical study reports obtained from the European and UK drug regulators.
Double-blind, placebo-controlled trials in adult healthy volunteers that reported on suicidality or violence or precursor events to suicidality or violence.
A total of 5787 publications were screened and 130 trials fulfilled our inclusion criteria. The trials were generally uninformative; 97 trials did not report the randomisation method, 75 trials did not report any discontinuations and 63 trials did not report any adverse events or lack thereof. Eleven of the 130 published trials and two of 29 clinical study reports we received from the regulatory agencies presented data for our meta-analysis. Treatment of adult healthy volunteers with antidepressants doubled their risk of harms related to suicidality and violence, odds ratio 1.85 (95% confidence interval 1.11 to 3.08, p = 0.02, I= 18%). The number needed to treat to harm one healthy person was 16 (95% confidence interval 8 to 100; Mantel-Haenszel risk difference 0.06). There can be little doubt that we underestimated the harms of antidepressants, as we only had access to the published articles for 11 of our 13 trials.
Antidepressants double the occurrence of events in adult healthy volunteers that can lead to suicide and violence.
量化在无精神障碍迹象的成年健康志愿者中使用选择性5-羟色胺再摄取抑制剂和5-羟色胺-去甲肾上腺素再摄取抑制剂时出现自杀倾向和暴力行为的风险。
系统评价和荟萃分析。
与自杀倾向、敌意、激越事件、精神病性事件和情绪障碍相关的危害。
通过检索PubMed和Embase数据库确定已发表的试验,并从欧洲和英国药品监管机构获取临床研究报告。
针对成年健康志愿者的双盲、安慰剂对照试验,这些试验报告了自杀倾向、暴力行为或自杀倾向或暴力行为的前驱事件。
共筛选了5787篇出版物,130项试验符合纳入标准。这些试验通常提供的信息不足;97项试验未报告随机分组方法,75项试验未报告任何停药情况,63项试验未报告任何不良事件或有无不良事件。我们从监管机构收到的130项已发表试验中的11项以及29项临床研究报告中的2项提供了用于荟萃分析的数据。用抗抑郁药治疗成年健康志愿者会使他们出现与自杀倾向和暴力行为相关危害的风险增加一倍,比值比为1.85(95%置信区间为1.11至3.08,p = 0.02,I = 18%)。使一名健康人受到伤害所需治疗的人数为16(95%置信区间为8至100;Mantel-Haenszel风险差为0.06)。毫无疑问,我们低估了抗抑郁药的危害,因为在我们的13项试验中,只有11项试验能获取已发表的文章。
抗抑郁药会使成年健康志愿者中可能导致自杀和暴力行为的事件发生率增加一倍。